Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1441-1460 of 1,782 trials

Ovarian Cancer: NIraparib and Dostarlimab Study

We are testing a new treatment combination for patients with recurrent ovarian cancer who cannot have platinum therapy. The study aims to see if this combination helps patients live longer compared to standard chemotherapy.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Melanoma Treatment: Vemurafenib, Cobimetinib, and Atezolizumab

We are studying a combination of three medications for patients with high-risk melanoma to see if it helps achieve a complete response. We also want to understand its effects on survival and safety.

High-Risk MelanomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Buspirone for Weak Esophageal Motility

We are studying whether buspirone can improve swallowing and esophageal function in patients with poor motility. This trial compares the effects of buspirone to a placebo on symptoms and esophageal pressure measurements.

Ineffective Motility or Absent Peristalsis≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteGastroenterology

Cholangiocarcinoma: SIRT and Capecitabine Study

We are evaluating a new treatment combining radiation therapy and chemotherapy for patients with operable intrahepatic cholangiocarcinoma. This study aims to see if this combination helps improve treatment outcomes before surgery.

Intrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

COPD: Atorvastatin for Reducing Exacerbations

We are studying whether atorvastatin can help reduce flare-ups in smokers with chronic obstructive pulmonary disease. The trial also looks at how this medication may affect lung function and quality of life.

Chronic Obstructive Pulmonary Disease>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicinePulmonology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Preventing Infections in ICU Patients with Interferon Gamma

We are studying whether interferon gamma can help prevent secondary infections in ICU patients with weakened immune systems. This research may improve recovery and reduce hospital stays.

Sustained Immunosuppression>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Head and Neck Cancer: Nivolumab and Ipilimumab Study

We are studying the effects of nivolumab alone and in combination with ipilimumab after surgery for head and neck cancer. This trial aims to see if these treatments can help patients stay cancer-free and how they affect quality of life.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Ovarian Cancer: Olaparib Maintenance Therapy

We are studying the effects of Olaparib as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer. This trial aims to understand its safety and how it may improve patient outcomes.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: Olaparib Treatment Study

We are investigating the effects of Olaparib in patients with recurrent ovarian cancer who do not have BRCA mutations. The goal is to see if it helps maintain treatment benefits after initial therapy and to understand its safety and effectiveness.

Recurrent Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Recurrent Ovarian Cancer: Olaparib vs. Chemotherapy

We are studying whether olaparib can help patients with recurrent ovarian cancer live longer without disease progression after surgery, compared to standard chemotherapy. The trial also looks at safety and quality of life.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Rheumatoid Arthritis: Spironolactone Study

We are investigating whether spironolactone can help reduce symptoms in people with active rheumatoid arthritis. The study will also monitor safety and other health indicators.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Corticobasal Syndrome: Glycerol Phenylbutyrate Study

We are investigating whether glycerol phenylbutyrate can lower nerve damage markers in patients with corticobasal syndrome. This study will also look at the safety and tolerability of the treatment.

Corticobasal Syndrome6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineNeurology